1. Scrip
  2. >>Leadership

Merck & Co.'s Barr To Lead Clinical Development After Baynes Departs For Eikon

 
• By Jessica Merrill

Longtime R&D leader Roy Baynes is leaving Merck to become chief medical officer at the biotech start-up helmed by Merck's former R&D chief Roger Perlmutter.

Eliav Barr
Merck & Co.'s Eliav Barr • Source: Merck & Co.

Merck & Co., Inc.'s longtime leader of global clinical development, chief medical officer Roy Baynes, is leaving the company to work with his former boss Roger Perlmutter at the biotech start-up Eikon Therapeutics, Inc..

Baynes will be succeeded by another executive with a long tenure at Merck

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.